Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment
ObjectiveTo analyze the levels of serum CTCs and ctDNA in NSCLC patients receiving first-line EGFR-TKI treatment, and to explore the clinical value of CTCs and ctDNA detection in assessing the efficacy of treatment for advanced lung cancer. MethodsA total of 109 NSCLC patients receiving first-line E...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2025-05-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849716915374653440 |
|---|---|
| author | Rui FAN Yonghui WU Zhan GU Yanbin PENG Lixin WANG |
| author_facet | Rui FAN Yonghui WU Zhan GU Yanbin PENG Lixin WANG |
| author_sort | Rui FAN |
| collection | DOAJ |
| description | ObjectiveTo analyze the levels of serum CTCs and ctDNA in NSCLC patients receiving first-line EGFR-TKI treatment, and to explore the clinical value of CTCs and ctDNA detection in assessing the efficacy of treatment for advanced lung cancer. MethodsA total of 109 NSCLC patients receiving first-line EGFR-TKI treatment were enrolled. Serum tumor markers CEA, CTCs, and ctDNA were detected at baseline and after one month of treatment. Chest CT scans were performed, and treatment efficacy was evaluated based on RECIST1.1 criteria. CTCs were counted by enrichment-staining-computational algorithm to analyze malignant features, while ctDNA was assessed using digital PCR. ResultsSurvival rate was low in patients with abnormal CEA and ctDNA tests at baseline and in patients with reduced serum CTCs after treatment. In the SD subgroup of patients with brain metastases and advanced stage, the PFS benefit was low. ConclusionPatients in the SD subgroup have significantly higher recurrence risks than those in the PR or CR subgroups. Therefore, CTC and ctDNA testing should be applied to patients in the SD subgroup to identify high-risk patients with poor response to EGFR-TKI treatment, intervene with additional treatment promptly, and obtain long progression-free survival. |
| format | Article |
| id | doaj-art-b8b85bea8fdb4918809ffddcba8c4476 |
| institution | DOAJ |
| issn | 1000-8578 |
| language | zho |
| publishDate | 2025-05-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj-art-b8b85bea8fdb4918809ffddcba8c44762025-08-20T03:12:50ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782025-05-0152538238710.3971/j.issn.1000-8578.2025.24.101720241017Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC TreatmentRui FAN0Yonghui WU1Zhan GU2Yanbin PENG3Lixin WANG4Department of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, ChinaObjectiveTo analyze the levels of serum CTCs and ctDNA in NSCLC patients receiving first-line EGFR-TKI treatment, and to explore the clinical value of CTCs and ctDNA detection in assessing the efficacy of treatment for advanced lung cancer. MethodsA total of 109 NSCLC patients receiving first-line EGFR-TKI treatment were enrolled. Serum tumor markers CEA, CTCs, and ctDNA were detected at baseline and after one month of treatment. Chest CT scans were performed, and treatment efficacy was evaluated based on RECIST1.1 criteria. CTCs were counted by enrichment-staining-computational algorithm to analyze malignant features, while ctDNA was assessed using digital PCR. ResultsSurvival rate was low in patients with abnormal CEA and ctDNA tests at baseline and in patients with reduced serum CTCs after treatment. In the SD subgroup of patients with brain metastases and advanced stage, the PFS benefit was low. ConclusionPatients in the SD subgroup have significantly higher recurrence risks than those in the PR or CR subgroups. Therefore, CTC and ctDNA testing should be applied to patients in the SD subgroup to identify high-risk patients with poor response to EGFR-TKI treatment, intervene with additional treatment promptly, and obtain long progression-free survival.http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1017advanced nsclcegfr-tkiefficacycirculating tumor cellscirculating tumor dna |
| spellingShingle | Rui FAN Yonghui WU Zhan GU Yanbin PENG Lixin WANG Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment Zhongliu Fangzhi Yanjiu advanced nsclc egfr-tki efficacy circulating tumor cells circulating tumor dna |
| title | Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment |
| title_full | Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment |
| title_fullStr | Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment |
| title_full_unstemmed | Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment |
| title_short | Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment |
| title_sort | evaluation value of blood biomarker tests for efficacy of egfr tki in advanced nsclc treatment |
| topic | advanced nsclc egfr-tki efficacy circulating tumor cells circulating tumor dna |
| url | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1017 |
| work_keys_str_mv | AT ruifan evaluationvalueofbloodbiomarkertestsforefficacyofegfrtkiinadvancednsclctreatment AT yonghuiwu evaluationvalueofbloodbiomarkertestsforefficacyofegfrtkiinadvancednsclctreatment AT zhangu evaluationvalueofbloodbiomarkertestsforefficacyofegfrtkiinadvancednsclctreatment AT yanbinpeng evaluationvalueofbloodbiomarkertestsforefficacyofegfrtkiinadvancednsclctreatment AT lixinwang evaluationvalueofbloodbiomarkertestsforefficacyofegfrtkiinadvancednsclctreatment |